LOGIN  |  REGISTER
Viking Therapeutics

Mettler-Toledo to Present at Upcoming Investor Conferences

November 01, 2024 | Last Trade: US$1,321.06 8.72 0.66

COLUMBUS, Ohio / Nov 01, 2024 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the UBS Global Healthcare Conference on Wednesday, November 13 at 11 a.m. EST, and the Stifel Healthcare Conference on Tuesday, November 19 at 1:15 p.m. EST.

The Company will also present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 9:10 a.m. EST. A live webcast of the presentations will be available on the Company’s investor relations website at investor.mt.com.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page